Grants Search Results

Need help? Call us at (888) 899-2253

Interested in applying for a St. Baldrick's Foundation grant? Learn more about the grant application process.

Showing 161-180 of 262 results

Funded: 07-01-2015 through 06-30-2022
Funding Type: Consortium Research Grant
Institution Location: Cambridge, United Kingdom
Institution: Cambridge University Hospitals

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Funded: 07-01-2015 through 06-30-2022
Funding Type: Consortium Research Grant
Institution Location: Atlanta, GA
Institution: Emory University affiliated with Children's Healthcare of Atlanta, Children's Healthcare of Atlanta at Egleston, Aflac Cancer Center

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Funded: 07-01-2015 through 06-30-2022
Funding Type: Consortium Research Grant
Institution Location: New Haven, CT
Institution: Yale University affiliated with Yale-New Haven Children's Hospital

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Funded: 07-01-2015 through 06-30-2022
Funding Type: Consortium Research Grant
Institution Location: Los Angeles, CA
Institution: University of Southern California

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Funded: 07-01-2015 through 06-30-2022
Funding Type: Consortium Research Grant
Institution Location: Toronto, ON
Institution: Hospital for Sick Children

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Funded: 07-01-2015 through 06-30-2022
Funding Type: Consortium Research Grant
Institution Location: Leeds, United Kingdom
Institution: University of Leeds

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Funded: 07-01-2015 through 06-30-2022
Funding Type: Consortium Research Grant
Institution Location: London, United Kingdom
Institution: University College London Hospitals

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Christopher French M.D. 

Researcher Photo

Funded: 07-01-2015 through 06-30-2016
Funding Type: Research Grant
Institution Location: Boston, MA
Institution: Brigham and Women's Hospital, Inc.

Dr. French's research focuses on a deadly cancer of children and young adults called NUT midline carcinoma. A while back Dr. French discovered the cancer protein that causes this disease, called BRD4-NUT. This discovery led to the development of inhibitors to BRD4 that are now being used to treat NUT midline carcinoma and this has expanded to the treatment of more common cancers in clinical trials. However, NUT midline carcinoma remains incurable. Recently, Dr. French discovered an additional and completely new protein that associates with BRD4-NUT, called a ZNF532, that helps BRD4-NUT cause this cancer. This research aims to understand how this new cancer protein contributes to the malignancy in this disease.

Jason Mendoza M.D., M.P.H.

Researcher Photo

Funded: 07-01-2015 through 06-30-2017
Funding Type: Supportive Care Research Grant
Institution Location: Seattle, WA
Institution: Seattle Children's Hospital affiliated with Fred Hutchinson Cancer Research Center, University of Washington

By increasing physical activity, survivors may reduce their risk of obesity and chronic diseases, and improve their quality of life. Dr. Mendoza's research aims to examine the use of a wearable physical activity device, the Fitbit, paired with a Facebook group, to increase physical activity among teen childhood cancer survivors. This approach aims to harness new wearable technology and the widespread use of smart phones to use individual- and peer-influences to promote physical activity.

Lisa Schwartz Ph.D.

Researcher Photo

Funded: 07-01-2015 through 06-30-2018
Funding Type: Supportive Care Research Grant
Institution Location: Philadelphia, PA
Institution: The Children's Hospital of Philadelphia affiliated with University of Pennsylvania

Adolescents and young adults with cancer do not receive adequate support and face a higher rate of relapse relative to younger patients. Dr. Schwartz's project is taking a current texting intervention which aims to improve health-related knowledge and engagement, and upgrading the technology and content in order to maximize the impact. This research aims to ultimately help improve the health and well-being of adolescents and young adults with cancer.

James Hu M.D.

Funded: 01-01-2015 through 06-30-2016
Funding Type: Infrastructure Grant
Institution Location: Los Angeles, CA
Institution: University of Southern California

This grant funds personnel at the AYA@USC program to help enroll more patients and build a database for adolescent and young adult studies.

Theodore B. Moore M.D.

Researcher Photo

Funded: 01-01-2015 through 12-31-2015
Funding Type: Infrastructure Grant
Institution Location: Los Angeles, CA
Institution: University of California, Los Angeles affiliated with Mattel Children's Hospital

This grant funds personnel support for clinical trials targeted at adolescents and young adults in a designated adolescent young adult unit.

Cheryl Willman M.D.

Funded: 07-01-2014 through 06-30-2015
Funding Type: Research Grant
Institution Location: Albuquerque, NM
Institution: University of New Mexico Health Sciences Center affiliated with UNM Children's Hospital

While many children with leukemia experience good outcomes on modern therapies, there are a large number of children who still relapse and die of their disease. Using new methods, Dr. Willman identified a new form of leukemia, called Ph-like ALL, which has a variety of gene mutations which code for enzymes. Currently, drugs that inhibit these enzymes are available for clinical trials. Dr. Willman is testing these drugs in children with high risk leukemia. This research aims to extend Dr. Willman's current studies to include children with standard risk leukemia in order to also improve their chances of survival.

Helen Parsons Ph.D.

Researcher Photo

Funded: 01-01-2014 through 06-01-2015
Funding Type: Infrastructure Grant
Institution Location: San Antonio, TX
Institution: University of Texas Health Science Center at San Antonio

This grant provides resources to help build an AYA Survivorship Program, to ensure that more adolescents and young adults can be treated on clinical trials, and to provide survivorship planning.

Karim Sadak M.D.

Researcher Photo

Funded: 01-01-2014 through 12-31-2014
Funding Type: Infrastructure Grant
Institution Location: Minneapolis, MN
Institution: University of Minnesota - Twin Cities affiliated with Masonic Children's Hospital

This grant funds a Clinical Research Associate to further develop and enhance the survivor program and develop effective outreach to this population.

Laurence Baker D.O.

Researcher Photo

Funded: 12-01-2013 through 11-30-2014
Funding Type: Infrastructure Grant
Institution Location: Ann Arbor, MI
Institution: University of Michigan affiliated with C.S. Mott Children’s Hospital

This grant provides resources to establish a soft tissue sarcoma subspecialty team to improve patient outcomes and ensure the best transition for adults from pediatric survival clinic to adult care.

John Gates M.D.

Researcher Photo

Funded: 12-01-2013 through 12-31-2015
Funding Type: Infrastructure Grant
Institution Location: Madera, CA
Institution: Valley Children's Healthcare

This grant helps provide necessary resources for the Childhood Cancer Survivorship Program at this institution, enhancing research while providing childhood cancer survivors the support, treatment and education they need to prevent and address late effects.

Dina Hankin Ph.D.

Researcher Photo

Funded: 12-01-2013 through 11-30-2014
Funding Type: Infrastructure Grant
Institution Location: Oakland, CA
Institution: Children's Hospital and Research Center Oakland

This grant funds the sustainability of a comprehensive long-term follow-up program and expansion plans to create a transition program with the goal to monitor the medical and psychosocial issues that young cancer patients face as they enter into adulthood.

Maria Gramatges M.D.

Researcher Photo

Funded: 07-01-2013 through 08-31-2018
Funding Type: St. Baldrick's Scholar
Institution Location: Houston, TX
Institution: Baylor College of Medicine affiliated with Vannie E. Cook Jr. Children's Cancer and Hematology Clinic, Texas Children's Hospital

Based on progress to date, Dr. Gramatges was awarded new grants in 2016 and 2017 to fund additional years of this Scholar award. Acute myeloid leukemia (AML) is treated with intensive chemotherapy that results in treatment-related toxicities in 80% of patients, some so severe that the patient does not survive therapy. Dr. Gramatges's research investigates genetic markers characterizing the subpopulation of children and young adults with AML who are at risk for severe treatment-related toxicities. Validation of these markers may lead to upfront screening of individuals with newly diagnosed AML, and in cases where these markers are discovered, modifications to the treatment regimen and closer monitoring to reduce treatment-related morbidity and mortality in this disease.

Amit Sabnis M.D.

Researcher Photo

Funded: 07-01-2013 through 06-30-2016
Funding Type: St. Baldrick's Fellow
Institution Location: San Francisco, CA
Institution: University of California, San Francisco affiliated with UCSF Benioff Children's Hospital

Based on progress to date, Dr. Sabnis was awarded a new grant in 2015 to fund an optional third year of this fellowship. Cure rates for children and adolescents with metastatic rhabdomyosarcoma, the most common soft tissue sarcoma in childhood, remain poor despite decades of research. While researchers know the mutation, PAX3-FOXO1, that causes an aggressive form of this cancer, getting rid of the mutation does not kill cancer cells. Since PAX3-FOXO1 drives cells to create many new proteins, Dr. Sabnis hypothesizes that these cells depend on buffers that keep proteins from misfolding or clumping into toxic aggregates. This project tests whether blocking HSP70, one such buffer, specifically and effectively kills sarcoma cells. Understanding this vulnerability will open the way for better treatments.